Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Duloxetine 60–120 mg once daily versus placebo in generalized anxiety disorder
2004-002626-22Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Dec 2004
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in generalized anxiety disorder (GAD) comparing Duloxetine 60–120 mg once daily with Placebo (2 arms). Primary endpoint: Time to relapse during double-blind continuation therapy. Started Dec 2004; status: completed.
02
Drugs
duloxetine
03
Conditions
generalized anxiety disorder (GAD)
Beyond the preview
Go deeper on 2004-002626-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-002626-22.